Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Korosho to Preferentially Support High-Quality Clinical Research
June 20, 2011
- ASKA Spreading Risks in Production, Distribution to Ensure Stable Supplies
June 20, 2011
- Korosho Calls For Development of 3 Drugs Used Off-label
June 20, 2011
- Reform Council Sees ¥1.6 Tril. Increase in Healthcare/Nursing Expenditure in FY2015
June 20, 2011
- Top-3 Dispensing Pharmacy Chains Report Record-high Sales, Profits Driven by New Store Openings
June 20, 2011
- Infections Added as Serious ADE for Revlimid: Safety Info.
June 20, 2011
- Korosho's Expert Committee Proposes Creation of “Pediatric Cancer Hub Hospitals”
June 20, 2011
- Yakult: Pharmaceutical Sales Up 10.8% Driven by Elplat
June 13, 2011
- Mirabegron Recommended for Approval for Treatment of OAB
June 13, 2011
- DSP, Kyorin Announce Results of Domestic PII Trial of Ranirestat
June 13, 2011
- Ajinomoto: Pharma Operating Profits Down 32% due to Higher R&D Costs
June 13, 2011
- Korosho to Conduct Survey on Economic Conditions in Healthcare
June 13, 2011
- KW-6002 Found Effective for PD in Domestic PIII Study: Kyowa Kirin
June 13, 2011
- Asahi Kasei Pharma: Sales Up 3.4% Driven by 3.5-Fold Increase in Sales of Recomodulin
June 13, 2011
- Council to Discuss Revision of Copayments for OTC-like Drugs
June 13, 2011
- JAK Inhibitor Tofacitinib Reduces Symptoms of RA: Pfizer Inc.
June 13, 2011
- ASKA: First Net Loss since Merger due to Earthquake
June 13, 2011
- Industry FTC Revises GL on Business Entertainment Practices
June 13, 2011
- Taiyo to Announce New Business Strategy around October
June 13, 2011
- Torii: Double-digit Decreases in Profits
June 13, 2011
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…